MIRM
Closed
Mirum Pharmaceuticals Inc
48.39
-2.50 (-4.91%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 50.89
Day's Range: 48.235 - 50.71
Send
sign up or login to leave a comment!
When Written:
25
Mirum Pharmaceuticals Inc. is a biopharmaceutical company that focuses on developing and commercializing therapies for rare liver diseases. The company was founded in 2018 and is headquartered in Foster City, California. Mirum's lead product candidate is maralixibat, an investigational oral drug for the treatment of cholestatic liver diseases, including progressive familial intrahepatic cholestasis (PFIC) and Alagille syndrome. The company is also developing a pipeline of other product candidates for rare liver diseases. Mirum went public in October 2019 and is traded on the NASDAQ under the ticker symbol "MIRM".
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!
When Written:
25
Mirum Pharmaceuticals Inc. is a biopharmaceutical company that focuses on developing and commercializing therapies for rare liver diseases. The company was founded in 2018 and is headquartered in Foster City, California.
Mirum's lead product candidate is maralixibat, a therapy for the treatment of progressive familial intrahepatic cholestasis (PFIC). PFIC is a rare genetic disorder that affects the liver and can lead to liver failure. Maralixibat is currently in Phase 3 clinical trials, and Mirum plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the first half of 2021.
In addition to maralixibat, Mirum is also developing therapies for other rare liver diseases, including Alagille syndrome and biliary atresia.
Mirum is led by a team of experienced pharmaceutical executives and has partnerships with leading academic institutions and research organizations. The company is backed by top-tier venture capital firms and has raised over $300 million in funding to date.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Mirum's lead product candidate is maralixibat, a therapy for the treatment of progressive familial intrahepatic cholestasis (PFIC). PFIC is a rare genetic disorder that affects the liver and can lead to liver failure. Maralixibat is currently in Phase 3 clinical trials, and Mirum plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the first half of 2021.
In addition to maralixibat, Mirum is also developing therapies for other rare liver diseases, including Alagille syndrome and biliary atresia.
Mirum is led by a team of experienced pharmaceutical executives and has partnerships with leading academic institutions and research organizations. The company is backed by top-tier venture capital firms and has raised over $300 million in funding to date.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!